Spots Global Cancer Trial Database for stage iiic gastric cancer

Every month we try and update this database with for stage iiic gastric cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer	NCT00274885	Cancer	oxaliplatin management of t...	18 Years -	National Cancer Institute (NCI)
Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers	NCT01846520	Healthy Subject Localized Trans... Metastatic Tran... Psychosocial Ef... Recurrent Bladd... Recurrent Cervi... Recurrent Colon... Recurrent Gastr... Recurrent Ovari... Recurrent Ovari... Recurrent Pancr... Recurrent Recta... Recurrent Renal... Recurrent Trans... Recurrent Ureth... Recurrent Uteri... Regional Transi... Stage II Bladde... Stage II Renal ... Stage II Urethr... Stage IIA Cervi... Stage IIA Colon... Stage IIA Gastr... Stage IIA Ovari... Stage IIA Ovari... Stage IIA Pancr... Stage IIA Recta... Stage IIA Uteri... Stage IIB Cervi... Stage IIB Colon... Stage IIB Gastr... Stage IIB Ovari... Stage IIB Ovari... Stage IIB Pancr... Stage IIB Recta... Stage IIB Uteri... Stage IIC Colon... Stage IIC Ovari... Stage IIC Ovari... Stage IIC Recta... Stage III Bladd... Stage III Pancr... Stage III Renal... Stage III Ureth... Stage IIIA Cerv... Stage IIIA Colo... Stage IIIA Gast... Stage IIIA Ovar... Stage IIIA Ovar... Stage IIIA Rect... Stage IIIA Uter... Stage IIIB Cerv... Stage IIIB Colo... Stage IIIB Gast... Stage IIIB Ovar... Stage IIIB Ovar... Stage IIIB Rect... Stage IIIB Uter... Stage IIIC Colo... Stage IIIC Gast... Stage IIIC Ovar... Stage IIIC Ovar... Stage IIIC Rect... Stage IIIC Uter... Stage IV Bladde... Stage IV Gastri... Stage IV Ovaria... Stage IV Ovaria... Stage IV Pancre... Stage IV Renal ... Stage IV Urethr... Stage IVA Cervi... Stage IVA Colon... Stage IVA Recta... Stage IVA Uteri... Stage IVB Cervi... Stage IVB Colon... Stage IVB Recta... Stage IVB Uteri... Ureter Cancer Stage IIA Lung ... Stage IIB Lung ... Stage IIIA Lung... Stage IIIB Lung...	educational int... telephone-based... quality-of-life... questionnaire a...	18 Years -	City of Hope Medical Center
64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer	NCT01939275	Adenocarcinoma ... Diffuse Adenoca... Intestinal Aden... Mixed Adenocarc... Recurrent Gastr... Stage IA Gastri... Stage IB Gastri... Stage IIA Gastr... Stage IIB Gastr... Stage IIIA Gast... Stage IIIB Gast... Stage IIIC Gast... Stage IV Gastri...	copper Cu 64-DO... positron emissi... laboratory biom... Computed Tomogr...	18 Years -	City of Hope Medical Center
Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction	NCT00938470	Adenocarcinoma ... Esophageal Canc... Gastric Cancer	capecitabine docetaxel fluorouracil oxaliplatin radiation thera... therapeutic con...	18 Years -	Alliance for Clinical Trials in Oncology
S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer	NCT01498289	Adenocarcinoma ... Esophageal Canc... Gastric Cancer	FOLFOX regimen docetaxel fluorouracil irinotecan hydr... leucovorin calc... oxaliplatin	18 Years - 120 Years	SWOG Cancer Research Network
Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery	NCT01705340	Adenocarcinoma ... HER2-positive B... Male Breast Can... Recurrent Breas... Recurrent Esoph... Recurrent Gastr... Stage IIIC Brea... Stage IIIC Esop... Stage IIIC Gast... Stage IV Breast... Stage IV Esopha... Stage IV Gastri...	Akt inhibitor M... trastuzumab lapatinib ditos... laboratory biom...	18 Years -	National Cancer Institute (NCI)
64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer	NCT01939275	Adenocarcinoma ... Diffuse Adenoca... Intestinal Aden... Mixed Adenocarc... Recurrent Gastr... Stage IA Gastri... Stage IB Gastri... Stage IIA Gastr... Stage IIB Gastr... Stage IIIA Gast... Stage IIIB Gast... Stage IIIC Gast... Stage IV Gastri...	copper Cu 64-DO... positron emissi... laboratory biom... Computed Tomogr...	18 Years -	City of Hope Medical Center
Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer	NCT01212822	Adenocarcinoma ... Adenocarcinoma ... Diffuse Adenoca... Intestinal Aden... Mixed Adenocarc... Squamous Cell C... Stage IA Esopha... Stage IA Gastri... Stage IB Esopha... Stage IB Gastri... Stage IIA Esoph... Stage IIA Gastr... Stage IIB Esoph... Stage IIB Gastr... Stage IIIA Esop... Stage IIIA Gast... Stage IIIB Esop... Stage IIIB Gast... Stage IIIC Esop... Stage IIIC Gast...	bevacizumab oxaliplatin leucovorin calc... fluorouracil therapeutic con... laboratory biom...	18 Years -	Fox Chase Cancer Center
Symptom Control With or Without Docetaxel in Treating Patients With Relapsed Esophageal Cancer or Stomach Cancer	NCT00978549	Adenocarcinoma ... Esophageal Canc... Gastric Cancer Nausea and Vomi... Pain	docetaxel steroid therapy questionnaire a... nausea and vomi... pain therapy quality-of-life... standard follow... radiation thera...	18 Years -	National Cancer Institute (NCI)
Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies	NCT01643499	Acinar Cell Ade... Adenocarcinoma ... Adenocarcinoma ... Adult Primary C... Advanced Adult ... Cholangiocarcin... Cholangiocarcin... Diffuse Adenoca... Duct Cell Adeno... Intestinal Aden... Localized Unres... Metastatic Carc... Metastatic Extr... Mixed Adenocarc... Mucinous Adenoc... Mucinous Adenoc... Newly Diagnosed... Signet Ring Ade... Signet Ring Ade... Stage III Pancr... Stage IIIA Colo... Stage IIIA Gall... Stage IIIA Gast... Stage IIIA Rect... Stage IIIB Colo... Stage IIIB Gall... Stage IIIB Gast... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Gast... Stage IIIC Rect... Stage IV Gastri... Stage IV Pancre... Stage IVA Colon... Stage IVA Gallb... Stage IVA Recta... Stage IVB Colon... Stage IVB Gallb... Stage IVB Recta... Unresectable Ex...	oxaliplatin irinotecan hydr... leucovorin calc... fluorouracil laboratory biom...	18 Years -	University of Chicago
Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma	NCT00084604	Adenocarcinoma ... Diffuse Adenoca... Intestinal Aden... Mixed Adenocarc... Recurrent Gastr... Stage IIIA Gast... Stage IIIB Gast... Stage IIIC Gast... Stage IV Gastri...	irinotecan hydr... bevacizumab cisplatin computed tomogr... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer	NCT01178944	Adenocarcinoma ... Esophageal Undi... Gastric Adenoca... Gastric Squamou... Recurrent Esoph... Recurrent Esoph... Recurrent Gastr... Stage IIIB Esop... Stage IIIB Esop... Stage IIIB Gast... Stage IIIC Esop... Stage IIIC Esop... Stage IIIC Gast... Stage IV Esopha... Stage IV Esopha... Stage IV Gastri... Undifferentiate...	Laboratory Biom... Oxaliplatin Pralatrexate	18 Years -	Roswell Park Cancer Institute
A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer	NCT00064259	Adenocarcinoma ... Adenocarcinoma ... Diffuse Adenoca... Intestinal Aden... Mixed Adenocarc... Recurrent Esoph... Recurrent Gastr... Squamous Cell C... Stage III Esoph... Stage IIIA Gast... Stage IIIB Gast... Stage IIIC Gast... Stage IV Esopha... Stage IV Gastri...	oblimersen sodi... cisplatin fluorouracil	19 Years -	National Cancer Institute (NCI)
Fluorouracil, Cisplatin, Leucovorin Calcium, and Cetuximab in Treating Patients With Adenocarcinoma of the Stomach or Gastroesophageal Junction	NCT01360086	Adenocarcinoma ... Gastric Cancer	cetuximab cisplatin fluorouracil leucovorin calc... adjuvant therap... neoadjuvant the... quality-of-life... therapeutic con...	18 Years - 75 Years	Federation Francophone de Cancerologie Digestive
64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer	NCT01939275	Adenocarcinoma ... Diffuse Adenoca... Intestinal Aden... Mixed Adenocarc... Recurrent Gastr... Stage IA Gastri... Stage IB Gastri... Stage IIA Gastr... Stage IIB Gastr... Stage IIIA Gast... Stage IIIB Gast... Stage IIIC Gast... Stage IV Gastri...	copper Cu 64-DO... positron emissi... laboratory biom... Computed Tomogr...	18 Years -	City of Hope Medical Center
A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer	NCT00064259	Adenocarcinoma ... Adenocarcinoma ... Diffuse Adenoca... Intestinal Aden... Mixed Adenocarc... Recurrent Esoph... Recurrent Gastr... Squamous Cell C... Stage III Esoph... Stage IIIA Gast... Stage IIIB Gast... Stage IIIC Gast... Stage IV Esopha... Stage IV Gastri...	oblimersen sodi... cisplatin fluorouracil	19 Years -	National Cancer Institute (NCI)
Study of Blood and Tissue Samples From Patients With Stomach Cancer, Esophageal Cancer, or Gastroesophageal Junction Cancer	NCT00963092	Adenocarcinoma ... Esophageal Canc... Gastric Cancer	DNA analysis RNA analysis microarray anal... protein analysi... cytology specim... laboratory biom... questionnaire a...	16 Years -	National Cancer Institute (NCI)
Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery	NCT01612546	Adenocarcinoma ... Adenocarcinoma ... Diffuse Adenoca... Intestinal Aden... Mixed Adenocarc... Recurrent Esoph... Recurrent Gastr... Squamous Cell C... Stage IIIB Esop... Stage IIIB Gast... Stage IIIC Esop... Stage IIIC Gast... Stage IV Esopha... Stage IV Gastri...	cyclodextrin-ba... Laboratory biom... Pharmacological...	18 Years -	City of Hope Medical Center
Symptom Control With or Without Docetaxel in Treating Patients With Relapsed Esophageal Cancer or Stomach Cancer	NCT00978549	Adenocarcinoma ... Esophageal Canc... Gastric Cancer Nausea and Vomi... Pain	docetaxel steroid therapy questionnaire a... nausea and vomi... pain therapy quality-of-life... standard follow... radiation thera...	18 Years -	National Cancer Institute (NCI)
Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer	NCT01123473	Adenocarcinoma ... Gastric Cancer	capecitabine cisplatin epirubicin hydr... fluorouracil lapatinib ditos...	18 Years - 75 Years	European Organisation for Research and Treatment of Cancer - EORTC
S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer	NCT01498289	Adenocarcinoma ... Esophageal Canc... Gastric Cancer	FOLFOX regimen docetaxel fluorouracil irinotecan hydr... leucovorin calc... oxaliplatin	18 Years - 120 Years	SWOG Cancer Research Network
C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer	NCT02344810	Adenocarcinoma ... Adenocarcinoma ... Diffuse Adenoca... Gastrointestina... Intestinal Aden... Mixed Adenocarc... Stage IIIA Esop... Stage IIIA Gast... Stage IIIB Esop... Stage IIIB Gast... Stage IIIC Esop... Stage IIIC Gast... Stage IV Esopha... Stage IV Gastri...	c-Met inhibitor... placebo oxaliplatin leucovorin calc... fluorouracil pharmacological... laboratory biom...	18 Years -	Eastern Cooperative Oncology Group
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer	NCT00982592	Adenocarcinoma ... Adenocarcinoma ... Recurrent Gastr... Stage IIIA Gast... Stage IIIB Gast... Stage IIIC Gast... Stage IV Gastri...	oxaliplatin leucovorin calc... fluorouracil placebo vismodegib laboratory biom...	18 Years -	National Cancer Institute (NCI)
Study of Blood and Tissue Samples From Patients With Stomach Cancer, Esophageal Cancer, or Gastroesophageal Junction Cancer	NCT00963092	Adenocarcinoma ... Esophageal Canc... Gastric Cancer	DNA analysis RNA analysis microarray anal... protein analysi... cytology specim... laboratory biom... questionnaire a...	16 Years -	National Cancer Institute (NCI)
Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer	NCT01212822	Adenocarcinoma ... Adenocarcinoma ... Diffuse Adenoca... Intestinal Aden... Mixed Adenocarc... Squamous Cell C... Stage IA Esopha... Stage IA Gastri... Stage IB Esopha... Stage IB Gastri... Stage IIA Esoph... Stage IIA Gastr... Stage IIB Esoph... Stage IIB Gastr... Stage IIIA Esop... Stage IIIA Gast... Stage IIIB Esop... Stage IIIB Gast... Stage IIIC Esop... Stage IIIC Gast...	bevacizumab oxaliplatin leucovorin calc... fluorouracil therapeutic con... laboratory biom...	18 Years -	Fox Chase Cancer Center
Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery	NCT01705340	Adenocarcinoma ... HER2-positive B... Male Breast Can... Recurrent Breas... Recurrent Esoph... Recurrent Gastr... Stage IIIC Brea... Stage IIIC Esop... Stage IIIC Gast... Stage IV Breast... Stage IV Esopha... Stage IV Gastri...	Akt inhibitor M... trastuzumab lapatinib ditos... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Electronic Monitoring Device of Patient-Reported Outcomes and Function in Improving Patient-Centered Care in Patients With Gastrointestinal Cancer Undergoing Surgery	NCT02511821	Stage I Adult L... Stage I Colorec... Stage IA Gastri... Stage IA Pancre... Stage IB Gastri... Stage IB Pancre... Stage II Adult ... Stage IIA Color... Stage IIA Gastr... Stage IIA Pancr... Stage IIB Color... Stage IIB Gastr... Stage IIB Pancr... Stage IIC Color... Stage III Pancr... Stage IIIA Adul... Stage IIIA Colo... Stage IIIA Gast... Stage IIIB Adul... Stage IIIB Colo... Stage IIIB Gast... Stage IIIC Adul... Stage IIIC Colo... Stage IIIC Gast... Stage IV Gastri... Stage IVA Color... Stage IVA Liver... Stage IVA Pancr... Stage IVB Color... Stage IVB Liver... Stage IVB Pancr...	Computer-Assist... Vivofit watch Quality-of-Life... Questionnaire A...	21 Years -	City of Hope Medical Center
Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery	NCT00991952	Adenocarcinoma ... Diffuse Adenoca... Intestinal Aden... Mixed Adenocarc... Recurrent Gastr... Stage IIIA Gast... Stage IIIB Gast... Stage IIIC Gast... Stage IV Gastri...	alvocidib irinotecan hydr... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma	NCT00084604	Adenocarcinoma ... Diffuse Adenoca... Intestinal Aden... Mixed Adenocarc... Recurrent Gastr... Stage IIIA Gast... Stage IIIB Gast... Stage IIIC Gast... Stage IV Gastri...	irinotecan hydr... bevacizumab cisplatin computed tomogr... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies	NCT01643499	Acinar Cell Ade... Adenocarcinoma ... Adenocarcinoma ... Adult Primary C... Advanced Adult ... Cholangiocarcin... Cholangiocarcin... Diffuse Adenoca... Duct Cell Adeno... Intestinal Aden... Localized Unres... Metastatic Carc... Metastatic Extr... Mixed Adenocarc... Mucinous Adenoc... Mucinous Adenoc... Newly Diagnosed... Signet Ring Ade... Signet Ring Ade... Stage III Pancr... Stage IIIA Colo... Stage IIIA Gall... Stage IIIA Gast... Stage IIIA Rect... Stage IIIB Colo... Stage IIIB Gall... Stage IIIB Gast... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Gast... Stage IIIC Rect... Stage IV Gastri... Stage IV Pancre... Stage IVA Colon... Stage IVA Gallb... Stage IVA Recta... Stage IVB Colon... Stage IVB Gallb... Stage IVB Recta... Unresectable Ex...	oxaliplatin irinotecan hydr... leucovorin calc... fluorouracil laboratory biom...	18 Years -	University of Chicago
Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer	NCT01212822	Adenocarcinoma ... Adenocarcinoma ... Diffuse Adenoca... Intestinal Aden... Mixed Adenocarc... Squamous Cell C... Stage IA Esopha... Stage IA Gastri... Stage IB Esopha... Stage IB Gastri... Stage IIA Esoph... Stage IIA Gastr... Stage IIB Esoph... Stage IIB Gastr... Stage IIIA Esop... Stage IIIA Gast... Stage IIIB Esop... Stage IIIB Gast... Stage IIIC Esop... Stage IIIC Gast...	bevacizumab oxaliplatin leucovorin calc... fluorouracil therapeutic con... laboratory biom...	18 Years -	Fox Chase Cancer Center
Nab-PTX Plus S-1 and Sintilimab as Adjuvant Therapy in Patients With Stage IIIC Gastric Cancer	NCT04781413	Stage IIIC Gast...	Nab-PTX, Sintil...	18 Years - 80 Years	Ruijin Hospital
Nab-PTX Plus S-1 and Sintilimab as Adjuvant Therapy in Patients With Stage IIIC Gastric Cancer	NCT04781413	Stage IIIC Gast...	Nab-PTX, Sintil...	18 Years - 80 Years	Ruijin Hospital
Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach	NCT00061932	Adenocarcinoma ... Diffuse Adenoca... Intestinal Aden... Mixed Adenocarc... Recurrent Gastr... Stage IIIB Gast... Stage IIIC Gast... Stage IV Gastri...	bortezomib irinotecan	18 Years -	National Cancer Institute (NCI)
Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer	NCT01178944	Adenocarcinoma ... Esophageal Undi... Gastric Adenoca... Gastric Squamou... Recurrent Esoph... Recurrent Esoph... Recurrent Gastr... Stage IIIB Esop... Stage IIIB Esop... Stage IIIB Gast... Stage IIIC Esop... Stage IIIC Esop... Stage IIIC Gast... Stage IV Esopha... Stage IV Esopha... Stage IV Gastri... Undifferentiate...	Laboratory Biom... Oxaliplatin Pralatrexate	18 Years -	Roswell Park Cancer Institute
Oxaliplatin and S-1 or Oxaliplatin and Capecitabine in Treating Patients With Recurrent, Metastatic, or Unresectable Gastric Cancer	NCT00985556	Gastric Cancer	capecitabine oxaliplatin tegafur-gimerac...	18 Years -	National Cancer Institute (NCI)
Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery	NCT01705340	Adenocarcinoma ... HER2-positive B... Male Breast Can... Recurrent Breas... Recurrent Esoph... Recurrent Gastr... Stage IIIC Brea... Stage IIIC Esop... Stage IIIC Gast... Stage IV Breast... Stage IV Esopha... Stage IV Gastri...	Akt inhibitor M... trastuzumab lapatinib ditos... laboratory biom...	18 Years -	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: